Genetic Analysis Balance Sheet Health
Financial Health criteria checks 3/6
Genetic Analysis has a total shareholder equity of NOK23.4M and total debt of NOK4.8M, which brings its debt-to-equity ratio to 20.5%. Its total assets and total liabilities are NOK41.6M and NOK18.2M respectively.
Key information
20.5%
Debt to equity ratio
NOK 4.80m
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 11.40m |
| Equity | NOK 23.43m |
| Total liabilities | NOK 18.19m |
| Total assets | NOK 41.62m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GEAN's short term assets (NOK21.2M) exceed its short term liabilities (NOK9.4M).
Long Term Liabilities: GEAN's short term assets (NOK21.2M) exceed its long term liabilities (NOK8.8M).
Debt to Equity History and Analysis
Debt Level: GEAN has more cash than its total debt.
Reducing Debt: GEAN's debt to equity ratio has increased from 4.5% to 20.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GEAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GEAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.6% each year